Progenics Pharmaceuticals, Inc. is a medicine developing company. The Company is engaged in developing medicines for oncology. Its focus for Progenics is targeted therapeutics and imaging agents. The Company’s clinical development efforts center on late-stage oncology assets. Its principal clinical-stage product candidates in oncology are PSMA ADC, 1404 (trofolastat) and Azedra. The Company’s product, Relistor, is a treatment for opioid-induced constipation (OIC). PSMA ADC is a human monoclonal antibody-drug conjugate designed to deliver a chemotherapeutic agent to cancer cells by targeting the three-dimensional structure of the PSMA protein. 1404 (trofolastat) is a radio-labeled small molecule, which binds PSMA and acts as an imaging agent to diagnose and detect prostate cancer. Azedra is a Phase 2 radiotherapeutic product candidate in development as a treatment for pheochromocytoma.